NYSE:ZYME

Zymeworks Stock Insider Trading

Healthcare > Biotechnology

Buy ZYME

*Your capital is at risk

$24.35

+0.240 (+1.00%)

At Close: Jun 03, 2026

Zymeworks Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 51.85. In total, the insiders bought 4.91M and sold 187.93K ZYME shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	51.85
● Buy	4.91M shares
● Sell	187.93K shares
90% Buy Activity Strong Negative Correlation
Sell Signal Low Confidence Jan 12, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 51.85. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 13, 2026 Buy	Restricted Stock Unit A-Award	Schneider Paul R EVP, General Counsel	Officer	119 000 Value: $2.92M
May 13, 2026 Buy	Stock Option (Right to Buy) A-Award	Schneider Paul R EVP, General Counsel	Officer	178 000 Value: $4.37M
May 13, 2026 Buy	No securities are beneficially owned	Schneider Paul R EVP, General Counsel	Officer	0 Value: $0
Apr 09, 2026 Buy	No securities are beneficially owned	Platshon Scott EVP, Chief Business Officer	Officer	0 Value: $0
Apr 09, 2026 Buy	No securities are beneficially owned	Schayowitz Adam See Remarks	Officer	0 Value: $0
Apr 09, 2026 Buy	Restricted Stock Unit	Schayowitz Adam See Remarks	Officer	111 111 Value: $3.04M
Apr 09, 2026 Buy	Performance Stock Unit A-Award	Platshon Scott EVP, Chief Business Officer	Officer	76 000 Value: $2.08M
Apr 09, 2026 Buy	Restricted Stock Unit A-Award	Schayowitz Adam See Remarks	Officer	47 000 Value: $1.29M
Apr 09, 2026 Buy	Performance Stock Unit A-Award	Schayowitz Adam See Remarks	Officer	76 000 Value: $2.08M
Apr 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Schayowitz Adam See Remarks	Officer	70 000 Value: $1.91M
Apr 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Platshon Scott EVP, Chief Business Officer	Officer	70 000 Value: $1.91M
Apr 09, 2026 Buy	Restricted Stock Unit A-Award	Platshon Scott EVP, Chief Business Officer	Officer	47 000 Value: $1.29M
Apr 09, 2026 Buy	Stock Option (Right to Buy)	Schayowitz Adam See Remarks	Officer	167 000 Value: $2.83M
Apr 09, 2026 Buy	Stock Option (Right to Buy)	Platshon Scott EVP, Chief Business Officer	Officer	167 000 Value: $3.84M
Apr 09, 2026 Buy	Restricted Stock Unit	Platshon Scott EVP, Chief Business Officer	Officer	111 111 Value: $3.04M
Apr 06, 2026 Buy	Restricted Stock Unit A-Award	Stafford Kristin EVP, Chief Financial Officer	C-Suite Officer	50 000 Value: $1.29M
Apr 06, 2026 Buy	Stock Option (Right to Buy) A-Award	Stafford Kristin EVP, Chief Financial Officer	C-Suite Officer	178 000 Value: $4.60M
Apr 06, 2026 Buy	Restricted Stock Unit A-Award	Stafford Kristin EVP, Chief Financial Officer	C-Suite Officer	119 000 Value: $3.07M
Apr 01, 2026 Buy	No securities are beneficially owned	Stafford Kristin EVP, Chief Financial Officer	C-Suite Officer	0 Value: $0
Feb 01, 2026 Buy	No securities are beneficially owned	Mekan Sabeen SVP & Chief Medical Officer	Officer	0 Value: $0
Feb 01, 2026 Buy	Performance Stock Unit	Mekan Sabeen SVP & Chief Medical Officer	Officer	32 000 Value: $779.2K
Feb 01, 2026 Buy	Restricted Stock Unit	Mekan Sabeen SVP & Chief Medical Officer	Officer	19 000 Value: $462.7K
Feb 01, 2026 Buy	Stock Option (Right to Buy)	Mekan Sabeen SVP & Chief Medical Officer	Officer	192 000 Value: $2.26M
Feb 01, 2026 Buy	Stock Option (Right to Buy)	Mekan Sabeen SVP & Chief Medical Officer	Officer	29 000 Value: $671.6K
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Cherry Brian N Director	Director	15 400 Value: $356.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ZYMEWORKS INC

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ...

Read Full Profile Here